Biofrontera (NASDAQ:BFRI – Get Free Report) and Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Profitability
This table compares Biofrontera and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biofrontera | -59.09% | -344.98% | -72.85% |
| Syndax Pharmaceuticals | N/A | -47.88% | -44.00% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Biofrontera and Syndax Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biofrontera | 0 | 0 | 1 | 0 | 3.00 |
| Syndax Pharmaceuticals | 0 | 1 | 9 | 0 | 2.90 |
Institutional & Insider Ownership
10.1% of Biofrontera shares are held by institutional investors. 0.7% of Biofrontera shares are held by company insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Biofrontera has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.
Valuation and Earnings
This table compares Biofrontera and Syndax Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biofrontera | $34.07 million | 0.22 | -$20.13 million | ($15.82) | -0.09 |
| Syndax Pharmaceuticals | $139.71 million | 12.75 | -$209.36 million | ($2.96) | -7.08 |
Biofrontera has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.
Summary
Syndax Pharmaceuticals beats Biofrontera on 9 of the 14 factors compared between the two stocks.
About Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
